178 related articles for article (PubMed ID: 36460729)
1. Caffeic acid N-[3,5-bis(trifluoromethyl)phenyl] amide as a non-steroidal inhibitor for steroid 5α-reductase type 1 using a human keratinocyte cell-based assay and molecular dynamics.
Lin ACK; Netcharoensirisuk P; Sanachai K; Sukma W; Chansriniyom C; Chaotham C; De-Eknamkul W; Rungrotmongkol T; Chamni S
Sci Rep; 2022 Dec; 12(1):20858. PubMed ID: 36460729
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
3. Carbon-chain length determines the binding affinity and inhibitory strength of per- and polyfluoroalkyl substances on human and rat steroid 5α-reductase 1 activity.
Cui R; Ye L; Qiao X; Wang S; Zheng K; Yang J; Ge RS; Lin H; Wang Y
Chem Biol Interact; 2024 May; 394():110987. PubMed ID: 38574835
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5alpha-reductases: determinants for different in vivo activities of GI198745 and finasteride in the rat.
Stuart JD; Lee FW; Simpson Noel D; Kadwell SH; Overton LK; Hoffman CR; Kost TA; Tippin TK; Yeager RL; Batchelor KW; Bramson HN
Biochem Pharmacol; 2001 Oct; 62(7):933-42. PubMed ID: 11543729
[TBL] [Abstract][Full Text] [Related]
5. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
6. Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man.
Hazlehurst JM; Oprescu AI; Nikolaou N; Di Guida R; Grinbergs AE; Davies NP; Flintham RB; Armstrong MJ; Taylor AE; Hughes BA; Yu J; Hodson L; Dunn WB; Tomlinson JW
J Clin Endocrinol Metab; 2016 Jan; 101(1):103-13. PubMed ID: 26574953
[TBL] [Abstract][Full Text] [Related]
7. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
Tindall DJ; Rittmaster RS
J Urol; 2008 Apr; 179(4):1235-42. PubMed ID: 18280514
[TBL] [Abstract][Full Text] [Related]
8. Steroid 5α-Reductase Type I Induces Cell Viability and Migration via Nuclear Factor-κB/Vascular Endothelial Growth Factor Signaling Pathway in Colorectal Cancer.
Wei R; Zhong S; Qiao L; Guo M; Shao M; Wang S; Jiang B; Yang Y; Gu C
Front Oncol; 2020; 10():1501. PubMed ID: 32983992
[TBL] [Abstract][Full Text] [Related]
9. The impact of finasteride and dutasteride treatments on proliferation, apoptosis, androgen receptor, 5α-reductase 1 and 5α-reductase 2 in TRAMP mouse prostates.
Opoku-Acheampong AB; Henningson JN; Lindshield BL
Heliyon; 2017 Jul; 3(7):e00360. PubMed ID: 28765837
[TBL] [Abstract][Full Text] [Related]
10. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
[TBL] [Abstract][Full Text] [Related]
11. Taxifolin Inhibits Neurosteroidogenic Rat Steroid 5α-Reductase 1 and 3α-Hydroxysteroid Dehydrogenase.
Su Y; Zhu Q; Hong X; Ge RS
Pharmacology; 2020; 105(7-8):397-404. PubMed ID: 31865316
[TBL] [Abstract][Full Text] [Related]
12. Structure of human steroid 5α-reductase 2 with the anti-androgen drug finasteride.
Xiao Q; Wang L; Supekar S; Shen T; Liu H; Ye F; Huang J; Fan H; Wei Z; Zhang C
Nat Commun; 2020 Oct; 11(1):5430. PubMed ID: 33110062
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer.
Das K; Lorena PD; Ng LK; Lim D; Shen L; Siow WY; Teh M; Reichardt JK; Salto-Tellez M
Endocr Relat Cancer; 2010 Sep; 17(3):757-70. PubMed ID: 20519274
[TBL] [Abstract][Full Text] [Related]
14. Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study.
Wei L; Lai EC; Kao-Yang YH; Walker BR; MacDonald TM; Andrew R
BMJ; 2019 Apr; 365():l1204. PubMed ID: 30971393
[TBL] [Abstract][Full Text] [Related]
15. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.
Litim N; Bourque M; Al Sweidi S; Morissette M; Di Paolo T
Neuropharmacology; 2015 Oct; 97():86-94. PubMed ID: 26006269
[TBL] [Abstract][Full Text] [Related]
16. Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride or Dutasteride for Male Androgenetic Alopecia.
Kang HW; Chae MH; Park SH; Seo SP; Kim WT; Kim YJ; Yun SJ; Lee SC; Yoon TY; Kim WJ
J Urol; 2017 Dec; 198(6):1340-1345. PubMed ID: 28743526
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride.
Makridakis N; Reichardt JK
J Mol Endocrinol; 2005 Jun; 34(3):617-23. PubMed ID: 15956333
[TBL] [Abstract][Full Text] [Related]
18. 5α-reductase type 1 modulates insulin sensitivity in men.
Upreti R; Hughes KA; Livingstone DE; Gray CD; Minns FC; Macfarlane DP; Marshall I; Stewart LH; Walker BR; Andrew R
J Clin Endocrinol Metab; 2014 Aug; 99(8):E1397-406. PubMed ID: 24823464
[TBL] [Abstract][Full Text] [Related]
19. Development of highly potent melanogenesis inhibitor by in vitro, in vivo and computational studies.
Abbas Q; Ashraf Z; Hassan M; Nadeem H; Latif M; Afzal S; Seo SY
Drug Des Devel Ther; 2017; 11():2029-2046. PubMed ID: 28740364
[TBL] [Abstract][Full Text] [Related]
20. Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
Festuccia C; Gravina GL; Muzi P; Pomante R; Angelucci A; Vicentini C; Bologna M
J Urol; 2008 Jul; 180(1):367-72. PubMed ID: 18499161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
